 Immune checkpoint inhibitors are a class of drugs that block certain proteins on T-cells, called checkpoints, which are essential for regulating the immune system. When these proteins are blocked, it allows the immune system to recognize and attack cancer cells, leading to improved survival rates in patients with different types of cancer. Immune checkpoint inhibitors are currently approved by the Food and Drug Administration FDA for the treatment of melanoma, hepatocellular carcinoma, endometrial carcinoma, non-small cell lung cancer, renal cell carcinoma, and bladder cancer. The most common side effects associated with immune checkpoint inhibitor therapies include fatigue, skin rashes, and fever. However, there have been reports of more severe side effects, such as cardiac toxicity and inflammation in the gastrointestinal tract or lungs. Despite this, immune checkpoint inhibitors have proven to be effective in treating many types of cancer, and they are being studied further for their potential use in combination with other cancer treatments. This article was authored by Nora A.L. Turkey. We are article.tv. Links in the description below.